SCHEMBL2167980

SCHEMBL2167980

CC(C)CN1CCCCC1C(C)O

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
SLC6A9 P48067 2/20 0.35
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32
TSHR P16473 1/20 0.32
KDM4E B2RXH2 1/20 0.31
PER2 O15055 1/20 0.31
CRY1 Q16526 1/20 0.31
CRY2 Q49AN0 1/20 0.31
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL28358042 0.92 CNR1 (0.34) CNR1CNR2SLC6A9LMNAMAPT
SCHEMBL7047205 0.82 L3MBTL1 (0.37) SLC6A9LMNAMEN1ALDH1A1KMT2A
SCHEMBL5142659 0.81 CNR1 (0.33) CNR1CNR2SLC6A9MAPTALDH1A1
SCHEMBL18199163 0.78 SLC6A9 (0.38) SLC6A9PIK3CD
SCHEMBL13416610 0.78 SLC6A9 (0.38) SLC6A9PIK3CD
SCHEMBL9340450 0.77 S1PR1 (0.40) TSHR
SCHEMBL31474253 0.76 L3MBTL1 (0.41) MEN1ALDH1A1KMT2A
SCHEMBL9044432 0.74 SLC6A1 (0.32)
SCHEMBL23374594 0.74 LMNA (0.46) LMNAMAPTMEN1ALDH1A1KMT2A
SCHEMBL23374635 0.74 LMNA (0.46) LMNAMAPTMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338539-A1 LAMELLAR GEL BASED PERSONAL CARE COMPOSITIONS, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC 2021-11-04 US claimed
EP-3852716-A1 LAMELLAR GEL BASED PERSONAL CARE COMPOSITIONS, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP Investments LLC (US) 2021-07-28 EP claimed
WO-2020061556-A1 LAMELLAR GEL BASED PERSONAL CARE COMPOSITIONS, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC (US) 2020-03-26 WO claimed
EP-1337146-B1 AEROSOL INSECT REPELLENT COMPOSITION HAVING LOW VOC CONTENT AND METHOD OF APPLYING SAME TO THE SKIN AVON PROD INC (US) 2006-02-08 EP claimed
WO-2002043491-A9 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PROD INC (US) 2003-08-14 WO claimed
EP-1250043-A4 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PROD INC (US) 2003-04-02 EP claimed
EP-1250043-A1 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PRODUCTS, INC. (US) 2002-10-23 EP claimed
WO-2002043491-A1 EXTENDED DURATION INSECT REPELLENT COMPOSITION AND METHOD OF APPLICATION TO THE SKIN AVON PRODUCTS, INC. (US) 2002-06-06 WO claimed
US-20230293406-A1 Compositions Comprising (Bio)-Alkanediols and Cooling Agents SYMRISE AG (DE) 2023-09-21 US disclosed
US-20230248626-A1 Compositions Comprising (Bio)-Alkanediols SYMRISE AG (DE) 2023-08-10 US disclosed
US-20210338539-A1 LAMELLAR GEL BASED PERSONAL CARE COMPOSITIONS, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF ISP INVESTMENTS LLC 2021-11-04 US disclosed
EP-1978803-B1 INSECT REPELLENT COMPOSITION DARLING SAMUEL T (CA) 2016-04-06 EP disclosed
US-8501205-B2 Insect repellent composition NO MO FOUNDATION 2013-08-06 US disclosed
US-20110183017-A1 INSECT REPELLENT COMPOSITION NO MO FOUNDATION 2011-07-28 US disclosed
US-7846464-B2 Insect repellent composition NO MO FOUNDATION 2010-12-07 US disclosed
EP-1978803-A2 INSECT REPELLENT COMPOSITION Darling, Samuel T. (CA) 2008-10-15 EP disclosed
WO-2007082306-A2 INSECT REPELLENT COMPOSITION DARLING SAMUEL T (CA) 2007-07-19 WO disclosed
US-20070166342-A1 INSECT REPELLENT COMPOSITION NO MO FOUNDATION 2007-07-19 US disclosed
WO-2007011586-A1 HALLOYSITE MICROTUBULE PROCESSES, STRUCTURES, AND COMPOSITIONS TECHNOLOGY INNOVATIONS, LLC (US) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248626-A1 Compositions Comprising (Bio)-Alkanediols OR51E2, OR10J3, TRPA1 CNR1 633/4885CNR2 278/4885SLC6A9 4429/4885
US-20110183017-A1 INSECT REPELLENT COMPOSITION TRPM8, TRPV3, LSM8 CNR1 752/4885CNR2 806/4885SLC6A9 1824/4885
US-20070166342-A1 INSECT REPELLENT COMPOSITION TRPM8, TRPV3, LSM8 CNR1 752/4885CNR2 806/4885SLC6A9 1824/4885
US-20230293406-A1 Compositions Comprising (Bio)-Alkanediols and Cooling Agents OR51E2, MAL2, ADH1C CNR1 854/4885CNR2 328/4885SLC6A9 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.